Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory…
NCT00005061 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00005061 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors |
| Official title | A Phase I, Open Label Multiple Dose, Safety and Pharmacokinetic Study of Intravenously Administered Humanized Anti-VEGF Monoclonal Antibody (HuMV833) to Patients With Relapsed or Refractory Solid Tumors |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 20 |
| Start date | Dec 1, 1999 |
| Primary completion | Jun 1, 2001 |
| First posted | Apr 12, 2004 |
| Last update posted | Jul 18, 2012 |
| Countries | Netherlands, Sweden, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: